Immuneering Corp — Director's Dealing 2023

Feb 17, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2023-02-15

Reporting Person: Zeskind Benjamin J. (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-15	Stock Option	$4.25	A	352244	Acquired	2033-02-15	Class A Common Stock (352244)	Direct
2023-02-15	Stock Option	$4.68	A	21756	Acquired	2028-02-15	Class A Common Stock (21756)	Direct

Footnotes

F1: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027.

F2: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027.